Trapost

Trapost0.004%

Ophthalmic Solution

Travoprost

Opsonin Pharma Ltd.

Product Code : 17221
MRP 650.00
10% Off
Best PriceTk
/
1
Section

Medicine overview

Indications of Trapost 0.004%

Trapost 0.004% Eye Drops is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of or insufficiently responsive to another intraocular pressure lowering medication, as monotherapy or as adjunctive therapy.

Theropeutic Class

Drugs for miotics and glaucoma

Pharmacology

Trapost 0.004%, an isopropyl ester prodrug, is a synthetic prostaglandin F2 alpha analogue that is rapidly hydrolyzed by esterases in the cornea to its biologically active free acid. The travoporst free acid is potent and highly selective for the FP prostanoid receptor.Trapost 0.004% free acid is a selective FP prostanoid receptor agonist and is believed to reduce intraocular pressure by increasing the drainage of aqueous humor, which is done primarily through increased uveoscleral outflow and to a lesser extent, trabecular outflow facility.

Dosage & Administration of Trapost 0.004%

Use in adults: The recommended dose is one drops of Trapost 0.004% in the conjunctival sac of the affected eye (s) once daily in the evening, If more than one topical ophthalmic product is being used, the medicines must be administered at least 5 minutes apart. When substituting another ophthalmic antiglaucoma agent with Trapost 0.004%, discontinue the other agent and start the following day with Trapost 0.004%.Pediatric patients: The efficacy and safety of Trapost 0.004% eye drops in patients below the age of 18 years have not been established.

Dosage of Trapost 0.004%

Use in adults: The recommended dose is one drops of Trapost 0.004% in the conjunctival sac of the affected eye (s) once daily in the evening, If more than one topical ophthalmic product is being used, the medicines must be administered at least 5 minutes apart. When substituting another ophthalmic antiglaucoma agent with Trapost 0.004%, discontinue the other agent and start the following day with Trapost 0.004%.Pediatric patients: The efficacy and safety of Trapost 0.004% eye drops in patients below the age of 18 years have not been established.

Interaction of Trapost 0.004%

Reduced therapeutic effect with NSAIDs.

Contraindications

Trapost 0.004% eye drops is contraindicated in patients with hypersensitive to Trapost 0.004% or any excipients of this preparation.

Side Effects of Trapost 0.004%

The most frequently reported treatment-related side-effect is ocular hyperaemia.

Pregnancy & Lactation

There are no adequate and well-controlled clinical study En pregnant women. Trapost 0.004% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.It is not known whether the drug or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Trapost 0.004% is administered to a lactating woman.

Precautions & Warnings

Trapost 0.004% should be used with caution in patients with active intraocular inflammation (iritis/uveitis). Trapost 0.004% should not be administered while wearing contact lenses. Contact lenses should be removed prior to the administration of the solution. Lenses may be reinserted 15 minutes following administration of Trapost 0.004%.

Storage Conditions

Store in a cool, dry place and protected from light. Keep out of reach of children. Discard the container 4 weeks after opening.

Drug Classes

Drugs for miotics and glaucoma

Mode Of Action

Trapost 0.004%, an isopropyl ester prodrug, is a synthetic prostaglandin F2 alpha analogue that is rapidly hydrolyzed by esterases in the cornea to its biologically active free acid. The travoporst free acid is potent and highly selective for the FP prostanoid receptor.Trapost 0.004% free acid is a selective FP prostanoid receptor agonist and is believed to reduce intraocular pressure by increasing the drainage of aqueous humor, which is done primarily through increased uveoscleral outflow and to a lesser extent, trabecular outflow facility.

Pregnancy

There are no adequate and well-controlled clinical study En pregnant women. Trapost 0.004% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.It is not known whether the drug or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Trapost 0.004% is administered to a lactating woman.
Disclaimer

The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.